TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07753148: An Open-Label, Multi-Center Phase I Study to Investigate the Safety and Tolerability of REGN17235 in Patients With Clonal Cytopenia of Undetermined Significance and Low-Risk Myelodysplastic Syndrome With SF3B1 Mutation

Sponsor: Regeneron Pharmaceuticals · Phase: PHASE1 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 52 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$4,312,016

Rescue Site Savings

+$2,844,576

Unlock Full NCT07753148 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07753148 Rescue Dossier →